Kidney Cancer Clinical Trial
Official title:
The Efficacy and Safety of Irreversible Electroporation for the Ablation of Renal Masses: A Prospective, Human, In-Vivo Study.
Background:
Electroporation or electropermeabilisation is a novel technique with the potential to
overcome the main disadvantages of thermal ablation. It utilizes electric pulses, traveling
between two or more electrodes, to create 'nanopores' in the cell membrane. If the applied
current reaches a certain threshold these 'nanopores' become permanent resulting in cell
death. The use of electric current means that IRE is not susceptible to 'thermal sink'
leading to consistent ablation results. IRE ablation targets the cell membrane, sparing
tissue architecture and minimizing damage to blood vessels, nerves and the renal collecting
system.
The first in human studies have proven the safety of IRE for the ablation of small renal
masses. However the efficacy of IRE through histopathological examination of an ablated
renal tumour has not yet been studied, compromising the correct and scientific evaluation of
this new technology.
Primary Objectives:
- To determine the efficacy of IRE ablation of renal masses , measured by histopathologic
examination of the targeted tumour.
- To determine the safety of IRE ablation of renal masses, by evaluating device and
procedural adverse events.
Secondary Objectives:
- To evaluate the efficacy of MRI in the imaging of ablation success, extend of the
ablation zone, one and four weeks post IRE ablation.
- To evaluate the efficacy of CEUS in the imaging of ablation success, extend of the
ablation zone, one and four weeks post IRE ablation.
Population:
10 patients, age ≥ 18 years, presenting with a solid enhancing mass, who are candidates for
radical nephrectomy.
Intervention:
Eligible patients will receive IRE ablation of their renal mass 4 weeks prior to radical
nephrectomy. Follow-up at one and four weeks post IRE will be performed using MRI and CEUS
imaging. After radical nephrectomy histopathological examination will be performed to
evaluate IRE ablation success.
Rationale:
The past decades have shown an increase in the incidence of small renal masses (SRM). At the
moment laparoscopic partial nephrectomy is the 'golden standard' in treatment of SRMs.
Thermal ablation techniques are indicated in patients who are poor surgical candidates or
who have a predisposition to develop multiple tumours. Recent studies have shown thermal
ablation techniques to have similar long-term oncologic results. Downsides to thermal
ablation are the possible damage to vital structures in the vicinity of the ablation zone,
e.g. collecting system or intestine, and unpredictable results due to difficulty in
monitoring the ablation zone and 'thermal sink'.
Electroporation or electropermeabilisation is a novel technique with the potential to
overcome the main disadvantages of thermal ablation. It utilizes electric pulses, traveling
between two or more electrodes, to create 'nanopores' in the cell membrane. If the applied
current reaches a certain threshold these 'nanopores' become permanent resulting in cell
death. The use of electric current means that IRE is not susceptible to 'thermal sink'
leading to consistent ablation results. IRE ablation targets the cell membrane, sparing
tissue architecture and minimizing damage to blood vessels, nerves and the renal collecting
system.
The first in human studies have proven the safety of IRE for the ablation of small renal
masses. However the efficacy of IRE through histopathological examination of an ablated
renal tumour has not yet been studied, compromising the correct and scientific evaluation of
a new technology. This is the primary objective of this research project.
Objectives:
Primary Objectives:
- To determine the efficacy of IRE ablation of renal masses , measured by histopathologic
examination of the targeted tumour.
- To determine the safety of IRE ablation of renal masses, by evaluating device and
procedural adverse events.
Secondary Objectives:
- To evaluate the efficacy of MRI in the imaging of ablation success, extend of the
ablation zone, one and four weeks post IRE ablation.
- To evaluate the efficacy of CEUS in the imaging of ablation success, extend of the
ablation zone, one and four weeks post IRE ablation.
Study design:
This is a prospective, human, in-vivo pilot study. Study population: 10 patients, age ≥ 18
years, presented with a solid enhancing RM , who are candidates for radical nephrectomy.
Intervention:
Patients will receive IRE ablation of the RM, performed under general anaesthesia, 4 weeks
before radical nephrectomy. Follow-up at one and four weeks post IRE will be performed using
MRI and CEUS imaging. After radical nephrectomy histopathological examination will be
performed to evaluate IRE ablation success.
Main study parameters/endpoints:
Primary endpoints:
- The efficacy of IRE ablation of renal masses , measured by histopathologic examination
of the targeted tumour by an experienced genitourinary pathologist. Using
immunehistochemical staining to evaluate cell viability.
- The safety of IRE ablation of renal masses, by evaluating device and procedural adverse
events using CTCAE v4.0.
Secondary endpoints:
- The efficacy of MRI in the imaging of ablation success, extend of the ablation zone,
one and four weeks post IRE ablation. By comparing MRI imaging to the histopathological
examination results of the resected material.
- The efficacy of CEUS in the imaging of ablation success, extend of the ablation zone,
one and four weeks post IRE ablation. By comparing CEUS imaging to the
histopathological examination results of the resected material.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
There are no benefits for patients that participate in this study. Study participants will
be exposed to additional risk when compared to standard treatment. They will have to undergo
an additional procedure under general anaesthesia with muscle relaxation. The exposure to
ionizing radiation during the procedure has been estimated at 32 mSv. Patients have to be
informed about the risks of procedural complications. Information on the efficacy of IRE,
proven histopathologically, is a vital step in order to progress to long term follow-up
studies without tumour excision. So far no study has investigated the efficacy of IRE for
the ablation of renal tumours in this manner.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00541008 -
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Recruiting |
NCT00301990 -
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00467077 -
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00098943 -
NGR-TNF in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00089102 -
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00899860 -
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
|
N/A | |
Completed |
NCT00021021 -
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00006968 -
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
|
Phase 1/Phase 2 |